A recent study indicates that patients who discontinue popular GLP-1 drugs like Mounjaro or Wegovy tend to recover reduced body mass much more quickly than those who stop conventional lifestyle regimens.
Published data in a major medical journal demonstrates that while overweight individuals often shed a large proportion of their body weight while on the medication, the weight is regained at an average rate of 0.8 kg per month after stopping.
"Individuals using such drugs need to be cognizant of the danger of quick rebound weight gain when the therapy is stopped," cautioned expert Dr. Susan Jebb.
Such speed of regain implies a reversion to original mass in about 18 months.
Comparing Approaches
The study, which examined 37 of trials involving thousands of participants, contrasted the outcomes of GLP-1 agonists with conventional dieting.
The team point out that individuals who shed pounds through lifestyle changes alone usually have a less rapid creep back—approximately 0.1 kg a month—post-intervention.
The Reason for the Rapid Rebound
Doctors believe the mode of action of the injections explains the heightened weight return.
The injections copy a natural hormone called glucagon-like peptide-1, which moderates hunger.
"Sustained high doses of the hormone levels far above than normal might result in the system to generate a reduced amount of its own natural hormone, and could lessen responsiveness to its effects," said Dr. Adam Collins, a dietetics expert.
"Stopping of this GLP-1 'fix' means hunger is unsuppressed, making binge eating much more probable."
An Ongoing Disease?
Medical guidelines suggest the jabs for people with weight-linked health risks, alongside prescribed lifestyle changes.
Many experts say that, considering the significant potential of weight regain, the treatment might need to be long-term.
This perspective is echoed by drug manufacturers, who say that the findings "underscore the long-term nature of excess weight," similar to managing conditions like hypertension.
User Experiences
Individuals who have discontinued the medication describe a intense return of hunger.
"It was like a switch activating and you become ravenous," described one woman.
The struggle is compounded if users have not adopted lasting lifestyle or habit modifications during treatment.
Widespread Adoption
Figures show that a significant number of people in the UK have used these injections in the past year, with demand being substantial.
- Use is higher among females compared to males.
- The middle-aged age group shows the highest level of interest.
- A large proportion obtain the drugs through private healthcare rather than the NHS.
Finally, researchers emphasize that while the jabs are potent agents for shedding pounds, they are not a magic fix and lasting health benefits hinges on combined behavioural changes.